Creative and strategic approaches to financing
While the biopharma space is hot, the pandemic-stricken general economy is not. That can spell challenge for startup and early-stage biopharma companies dependent on investment dollars to keep the lights on and the talent on board. While biopharma investments might still be flowing, the game of securing that funding has changed. The investment community is more scrupulous, more discerning, and more cognizant of its own upstream money trail.
You’d be hard-pressed to find a biotech founder who knows these ropes as well as Dr. Ben Zeskind, CEO of Immuneering, which he founded in 2008 as the global economy suffered the beating that would come to pass as the Great Recession. Zeskind shared details on how the fund-seeking exercise changes in challenging economies—and his strategies for addressing those changes—with The Business Of Biotech podcast (produced by BioProcess Online and supported by Cytiva).